Protagonist Therapeutics Inc. (PTGX) carries a Roarable Rating of C (Hold) with 65/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
As of 2026-11-03, Protagonist Therapeutics Inc. (NASDAQ: PTGX) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 65/100 at a spot price of $139.37 (-3.78% 1D, market cap $9.37B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 8/20. Across 1015 tracked Health Care issuers, PTGX ranks #115 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PTGX carries a Roarable C (65/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -16.7%. By comparison, TGTX (TG Therapeutics Inc.) holds a C grade (63/100 RQD, P/E 19.9x, ROIC 12.0%, cap $9.36B) and MDGL (Madrigal Pharmaceuticals Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -29.7%, cap $9.94B). Among the 5-stock peer group, TGTX leads on earnings multiple (19.9x) while TGTX leads on capital efficiency (12.0% ROIC).
Per PTGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001377121), Protagonist Therapeutics Inc. generated $442.8M in revenue (-37.5% YoY), -$130.1M in net income, and $56.1M in free cash flow against $668.2M in total assets and $24.1M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±7.9% realized swing band)
Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 6/9
Disciplined Float (+1.08% YoY Shares) & executive Form 4 sales trim 12 pts from alignment
Even with a 65/100 (C) score, PTGX faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Company executives have done more routine share selling than personal cash buying lately.
Dilution & Margin Drag: Disciplined Float (+1.08% YoY Shares) — any gross margin slip below 15.0% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($142.41) or 200D SMA ($117.54) invalidates the momentum regime and cuts Target Base ($143.76) toward Bear Floor ($112.13).
Protagonist Therapeutics Inc. (PTGX) dropped -3.78% to $139.37, trading at 75% of its 52-week range ($75.44 – $160.81). Solid steady margins (-17% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
Yahoo! Finance Canada report covering Protagonist Therapeutics Inc. (PTGX) market action, institutional positioning, and fundamental catalysts.
ChartMill report covering Protagonist Therapeutics Inc. (PTGX) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Protagonist Therapeutics Inc. (PTGX) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Protagonist Therapeutics Inc. (PTGX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Protagonist Therapeutics Inc. (PTGX) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Protagonist Therapeutics Inc. (PTGX) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Protagonist Therapeutics Inc. (PTGX) market action, institutional positioning, and fundamental catalysts.
PTGX blends strong technicals (9) and high growth momentum (6) with a Setup Rating of 7, nearing a breakout despite clinical-stage risks.
Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The mean of analysts' price targets for Protagonist Therapeutics (PTGX) points to a 25.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -37.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PTGX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PTGX. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Protagonist Therapeutics Inc. (PTGX) ranks #115 by composite RQD confidence (65/100, grade C) and #117 by equity capitalization ($9.37B). Within this direct 5-issuer industry benchmark cohort, TGTX leads on earnings valuation at 19.9x trailing P/E, while TGTX leads on capital efficiency and profitability with 12.0% ROIC and 83.7% gross margin. PTGX currently leads its immediate peer cohort in composite quantitative strength at 65/100 (C).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PTGX
ACTIVE
Protagonist Therapeutics Inc. | C | 65/100 | — | — | -16.7% | -3.78% | $9.37B | Benchmark Subject |
| TGTX TG Therapeutics Inc. | C | 63/100 | 19.9x | 83.7% | 12.0% | -2.01% | $9.36B | /tgtx-vs-ptgx → |
| MDGL Madrigal Pharmaceuticals Inc. | D- | 38/100 | — | — | -29.7% | +0.19% | $9.94B | /mdgl-vs-ptgx → |
| CORT Corcept Therapeutics Incorporated | C | 63/100 | 93.2x | 96.0% | 4.8% | -0.81% | $8.77B | /cort-vs-ptgx → |
| CYTK Cytokinetics Incorporated | E | 28/100 | — | — | -35.0% | -1.52% | $8.76B | /cytk-vs-ptgx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Protagonist Therapeutics Inc. (PTGX) reported GAAP revenue of $442.8M (-37.5% vs. FY2024 revenue of $708.0M , and +68.8% cumulative change since FY2023) , GAAP net income of -$130.1M, operating cash flow of $57.7M, and free cash flow of $56.1M (-69.3% YoY). On the balance sheet, PTGX closed FY2025 with $668.2M in total assets against $24.1M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $442.8M | -$130.1M | $57.7M | $56.1M | $668.2M | $24.1M |
| FY2024 (FY) | 2024-12-31 | $708.0M | $275.2M | $184.2M | $182.8M | $744.7M | $31.2M |
| FY2023 (FY) | 2023-12-31 | $262.2M | -$79.0M | -$70.2M | -$70.2M | $5.14B | $1.20B |
As of 2026-11-03, Protagonist Therapeutics Inc. (NASDAQ: PTGX) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 65/100 at a spot price of $139.37 (-3.78% 1D, market cap $9.37B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 8/20. Across 1015 tracked Health Care issuers, PTGX ranks #115 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PTGX carries a Roarable C (65/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -16.7%. By comparison, TGTX (TG Therapeutics Inc.) holds a C grade (63/100 RQD, P/E 19.9x, ROIC 12.0%, cap $9.36B) and MDGL (Madrigal Pharmaceuticals Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -29.7%, cap $9.94B). Among the 5-stock peer group, TGTX leads on earnings multiple (19.9x) while TGTX leads on capital efficiency (12.0% ROIC).
Per PTGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001377121), Protagonist Therapeutics Inc. generated $442.8M in revenue (-37.5% YoY), -$130.1M in net income, and $56.1M in free cash flow against $668.2M in total assets and $24.1M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
PTGX last traded at $139.37 (-3.78% on volume of 486,910 shares), positioning the stock -2.13% below its 50-day simple moving average ($142.41) and +18.57% above its 200-day simple moving average ($117.54). Across its 52-week range of $75.44 to $160.81, PTGX sits at the 74.9% percentile with a 14-day RSI of 57.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.9% ($128.36 to $150.38).
Protagonist Therapeutics Inc. (PTGX) earns a live Roarable RQD composite score of 65/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $139.37 (-3.78% 1D, market capitalization $9.37B).
Protagonist Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry,. Reported revenue is — across all listed periods so the source does not establish how the company generates income.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Protagonist Therapeutics Inc. (PTGX) reported $442.8M in annual revenue (up from $708.0M in FY2024, -37.5% YoY) and -$130.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($262.2M revenue, -$79.0M net income) through FY2025, PTGX scaled operating cash flow to $57.7M and free cash flow to $56.1M, backed by $668.2M in total assets against $24.1M in total debt.
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), PTGX carries a macro regime beta of 0.99 and gross margin of —.
Real-time company headlines, analyst actions, and sector developments for Protagonist Therapeutics Inc. (PTGX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Protagonist Therapeutics Inc. (PTGX) market action, institutional positioning, and fundamental catalysts.
ChartMill report covering Protagonist Therapeutics Inc. (PTGX) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Protagonist Therapeutics Inc. (PTGX) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Protagonist Therapeutics Inc. (PTGX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Protagonist Therapeutics Inc. (PTGX) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Protagonist Therapeutics Inc. (PTGX) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Protagonist Therapeutics Inc. (PTGX) market action, institutional positioning, and fundamental catalysts.
PTGX blends strong technicals (9) and high growth momentum (6) with a Setup Rating of 7, nearing a breakout despite clinical-stage risks.
Long PTGX at $144.85 targeting $173.82. Balance sheet strength (Altman Z 26, Debt/Equity 0.04) and institutional accumulation support the stock despite negative returns.. Institutional whale score is 16/20 and the risk/reward vs. the $75.44 52-week low is skewed heavily in favor of bulls.
@FadeTheHype Shorting a 16/20 institutional whale-flow stock at $144.85 is dangerous when funds are rotating into Health Care.
Here is the bear case nobody on the bull side wants to address on PTGX: Negative ROIC of -16.7%, FY 2025 net loss of -$130.1M, and a forward P/E of 31 against negative trailing EPS leave the valuation dependent on unproven earnings.. At 31.0x forward P/E, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: